VKTX Viking Therapeutics, Inc.
Healthcare$30.80-0.29%ClosedMarket Cap: $3.58B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
7.11
P/S
0.00
EV/EBITDA
-6.91
DCF Value
$1.03
FCF Yield
-9.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-71.3%
ROA
-77.7%
ROIC
-100.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-164.1M | $-158.3M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-164.7M | $-157.7M | $— | — |
| FY null | $0.00 | -Infinity% | $-393.3M | $-359.6M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-98.6M | $-90.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-74.6M | $-65.6M | $— | — |
| Q1 null | $0.00 | NaN% | $-55.5M | $-45.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-46.2M | $-35.4M | $— | — |
| FY null | $0.00 | NaN% | $-150.9M | $-110.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-36.6M | $-24.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-34.1M | $-22.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-34.1M | $-27.4M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-29.3M | $-24.6M | $-0.25 | — |